CAMBRIDGE, Mass., May 29, 2024
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for
clinically proven kinase targets in cancer, today announced that
James Porter, Ph.D., Chief Executive
Officer, and Alexandra Balcom, Chief
Financial Officer, will participate in a fireside chat during the
2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:30 p.m. ET in NYC.
A live webcast will be available in the Investors section of the
company's website at www.nuvalent.com, and archived for 30 days
following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a
clinical-stage biopharmaceutical company focused on creating
precisely targeted therapies for patients with cancer,
designed to overcome the limitations of existing therapies for
clinically proven kinase targets. Leveraging deep expertise in
chemistry and structure-based drug design, we develop innovative
small molecules that have the potential to overcome resistance,
minimize adverse events, address brain metastases, and drive more
durable responses. Nuvalent is advancing a robust pipeline with
investigational candidates for ROS1-positive, ALK-positive, and
HER2-altered non-small cell lung cancer, and multiple
discovery-stage research programs.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-2024-jefferies-global-healthcare-conference-302157212.html
SOURCE Nuvalent, Inc.